ClinicalTrials.gg
CompletedNCT04662151Updated Jul 3, 2024

A Clinical Safety Study of AT-100 (rhSP-D) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia (BPD)

A Phase 1 interventional study of AT-100 and Air-sham in Bronchopulmonary Dysplasia, sponsored by Airway Therapeutics, Inc.. Completed at 19 sites in 2 countries. Open to participants aged 0 Minutes to 96 Hours. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Airway Therapeutics, Inc. · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
0 Minutes to 96 Hours
Sex
All
01

Study summary

The purpose of this study is to determine if an investigational drug, AT-100, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature, as compared to babies born premature who receive an air-sham alone.

02

Conditions studied

  • Bronchopulmonary Dysplasia

Keywords

  • Bronchopulmonary Dysplasia
  • Preterm
  • Neonate
  • Mechanical ventilation
  • Respiratory support
  • recombinant human Surfactant Protein-D (rhSP-D)
  • intratracheal
  • air-sham
03

In context

Bronchopulmonary Dysplasia

362 studies on the registry are indexed under Bronchopulmonary Dysplasia; 84 are open to participants now.

This study's enrollment of 37 is below the median of 66 across 244 interventional studies indexed under Bronchopulmonary Dysplasia.

Browse Bronchopulmonary Dysplasia studies →

Lead sponsor

Airway Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Minutes to 96 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Preterm neonates born between Gestional Age (GA):

    1. 25 0/7 weeks to 28 6/7 weeks in the initial dose escalation cohorts.
    2. 23 0/7 weeks to 28 6/7 weeks in the latter cohort.
  2. Intubated and on mechanical ventilation.
  3. Receiving at least 1 dose of standard-of-care-indicated surfactant treatment (Curosurf®) after birth, and able to receive the first dose of AT-100 or air-sham within 96 hours of birth given at any time point after 15 minutes following any of the subject's Curosurf® dose(s).
  4. Parent or legal guardian is able to provide .

Exclusion criteria

Exclusion Criteria:

  1. Weight at time of birth \< 400 g or > 1,800 g.
  2. Major apparent congenital abnormalities impacting cardio and pulmonary function.
  3. Active DNR (Do Not Resuscitate) order in place.
  4. Known pulmonary air leaks (e.g. pneumothorax and pneumomediastinum) at the time of AT-100 or air-sham administration.
  5. History of allergy or sensitivity to any surfactant or any component of the Product (AT-100).
  6. AT-100 or air-sham dosing was set to occur before Data Safety Monitoring Committee recommendation to proceed to the next dose-escalation cohort.
  7. Use of minimally invasive surfactant techniques (e.g., LISA, MIST) or INSURE or if, in the opinion of the care team, the infant is very likely too be extubated shortly after receiving Curosurf®.

    a. Subjects extubated and re-intubated after their Curosurf® dose(s) are eligible, so long as the subject meets Inclusion #3.

  8. Birth mother:

    1. Has known active , C, or E diagnosis.
    2. Has a known illness or exposure that, in the judgement of the Investigator, is serious enough to induce an immune deficiency such as (HIV) and/or is receiving chemotherapy.
    3. Has known active Sexually Transmitted Infection (STI).
    4. Has known Cytomegalovirus (CMV) active infection.
    5. Has known history or evidence of alcohol or drug abuse, wit the exception of marijuana/marijuana-based products/THC, based on a positive maternal or infant drug screen as evidenced by the institution's standard-of-care practice.
  9. Concurrent enrollment in an investigational drug, device, or treatment modulation trial that utilizes treatments outside of standard-of-care.
  10. Any condition or situation which, in the Investigator's judgement, puts the mother or the neonate at significant risk, could confound the trial results, or may interfere significantly with the mother's or neonate's participation in the trial.
  11. Symptomatic and confirmed COVID-19 infection of the mother around the time of birth.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Phase 1b open-label AT-100

    Once daily AT-100 via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated \& safety dose level tested portion).

    Biological: AT-100

  • Sham comparator
    Phase 1b open-label air-sham

    Once daily air-sham via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated \& safety dose level tested portion).

    Procedure: Air-sham

Interventions

  • BiologicalAT-100

    reconstituted AT-100 for intratracheal administration

    Also known as: (rhSP-D)

  • ProcedureAir-sham

    room air for intratracheal administration

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events

    Incidence and severity of adverse events between the two treatment groups will be compared

    Time frame: Adverse events will be followed up to Day 28 of life

  2. Incidence of BPD or death

    Time frame: Week 36 PMA

07

Study locations

19 sites
  • Airway Therapeutics Investigational Site
    Tucson, Arizona 85724, United States
  • Airway Therapeutics Investigational Site
    Little Rock, Arkansas 72202, United States
  • Airway Therapeutics Investigational Site
    Los Angeles, California 90017, United States
  • Airway Therapeutics Investigational Site
    Miami, Florida 33143, United States
  • Airway Therapeutics Investigational Site
    Atlanta, Georgia 30308, United States
  • Airway Therapeutics Investigational Site
    Indianapolis, Indiana 46202, United States
  • Airway Therapeutics Investigational Site
    Boston, Massachusetts 02215, United States
  • Airway Therapeutics Investigational Site
    Durham, North Carolina 27705, United States
  • Airway Therapeutics Investigational Site
    Norfolk, Virginia 23507, United States
  • Airway Therapeutics Investigational Site
    Cadiz, Andalucia 11009, Spain
  • Airway Therapeutics Investigational Site
    Barcelona, Cataluña 08041, Spain
  • Airway Therapeutics Investigational Site
    Madrid, Comunidad De Madrid 28007, Spain
  • Airway Therapeutics Investigational Site
    Madrid, Comunidad De Madrid 28046, Spain
  • Airway Therapeutics Investigational Site
    Alicante, Comunidad Valenciana 03010, Spain
  • Airway Therapeutics Investigational Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Airway Therapeutics Investigational Site
    Santiago De Compostela, Galicia 15706, Spain
  • Airway Therapeutics Investigational Site
    A Coruña, 15006, Spain
  • Airway Therapeutics Investigational Site
    Lleida, 25198, Spain
  • Airway Therapeutics Investigational Site
    Málaga, 29010, Spain
08

References and documents

Publications

  • Thebaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, Aschner JL, Davis PG, McGrath-Morrow SA, Soll RF, Jobe AH. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019 Nov 14;5(1):78. doi: 10.1038/s41572-019-0127-7. PubMed 31727986 ↗
  • Jensen EA, Dysart K, Gantz MG, McDonald S, Bamat NA, Keszler M, Kirpalani H, Laughon MM, Poindexter BB, Duncan AF, Yoder BA, Eichenwald EC, DeMauro SB. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med. 2019 Sep 15;200(6):751-759. doi: 10.1164/rccm.201812-2348OC. PubMed 30995069 ↗
  • Sorensen GL. Surfactant Protein D in Respiratory and Non-Respiratory Diseases. Front Med (Lausanne). 2018 Feb 8;5:18. doi: 10.3389/fmed.2018.00018. eCollection 2018. PubMed 29473039 ↗
  • Sato A, Whitsett JA, Scheule RK, Ikegami M. Surfactant protein-d inhibits lung inflammation caused by ventilation in premature newborn lambs. Am J Respir Crit Care Med. 2010 May 15;181(10):1098-105. doi: 10.1164/rccm.200912-1818OC. Epub 2010 Feb 4. PubMed 20133924 ↗
  • Ikegami M, Carter K, Bishop K, Yadav A, Masterjohn E, Brondyk W, Scheule RK, Whitsett JA. Intratracheal recombinant surfactant protein d prevents endotoxin shock in the newborn preterm lamb. Am J Respir Crit Care Med. 2006 Jun 15;173(12):1342-7. doi: 10.1164/rccm.200509-1485OC. Epub 2006 Mar 23. PubMed 16556693 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Aug 2023, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2020
First posted
Dec 10, 2020
StartActual
Sep 1, 2021
Primary completionActual
Aug 14, 2023
CompletionActual
May 29, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04662151
Lead sponsor
Airway Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 10, 2020
Start date
Sep 1, 2021
Primary completion
Aug 14, 2023
Completion
May 29, 2024
Last update
Jul 3, 2024

Study contacts

Marc O. Salzberg, MD
study chair · Airway Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zelpultide alfa

Start the discussion